Life and health span can be prolonged by calorie limitation or by pharmacologic agents that mimic the effects of caloric restriction. Both starvation and the genetic inactivation of nutrient signaling converge on the induction of autophagy, a cytoplasmic recycling process that counteracts the age-associated accumulation of damaged organelles and proteins as it improves the metabolic fitness of cells. Here we review experimental findings indicating that inhibition of the major nutrient and growth-related signaling pathways as well as the upregulation of anti-aging pathways mediate life span extension via the induction of autophagy. Furthermore, we discuss mounting evidence suggesting that autophagy is not only necessary but, at least in some cases, also sufficient for increasing longevity.
Essential role for autophagy in life span extension

Frank Madeo, Andreas Zimmermann, Maria Chiara Maiuri, and Guido Kroemer

Life and health span can be prolonged by calorie limitation or by pharmacologic agents that mimic the effects of caloric restriction. Both starvation and the genetic inactivation of nutrient signaling converge on the induction of autophagy, a cytoplasmic recycling process that counteracts the age-associated accumulation of damaged organelles and proteins as it improves the metabolic fitness of cells. Here we review experimental findings indicating that inhibition of the major nutrient and growth-related signaling pathways as well as the upregulation of anti-aging pathways mediate life span extension via the induction of autophagy. Furthermore, we discuss mounting evidence suggesting that autophagy is not only necessary but, at least in some cases, also sufficient for increasing longevity.

Introduction

One hallmark of aging is the accumulation of various forms of molecular damage, embodied in malfunctioning organelles, defective enzymes, proteinaceous aggregates, or DNA mutations (1). At the same time, the incidence of chronic diseases such as neurodegeneration, type II diabetes, or cancer rises with age concomitantly with accumulating cellular damage. Therefore, one of the main challenges for future medicine is the development of strategies to prolong health span (i.e., maintaining a healthy state without necessarily extending the maximum life span) by subverting the etiology of age-related disorders rather than solely providing symptomatic treatments. One of the most promising toeholds in the ascension toward a causal treatment of aging is autophagy, a cellular program for the removal of damaged cellular components and the digestion of cell-intrinsic macromolecules in the context of dwindling nutritional resources. Since lysosomes were first described in the 1950s (2, 3), a spectrum of different lysosome-mediated degradation pathways has been discovered.Macroautophagy (hereafter referred to as autophagy) constitutes a mechanism through which cytoplasmic organelles or cytosolic molecules are sequestered in double-membrane vesicles, so-called autophagosomes, that subsequently fuse with lysosomes for bulk digestion of the autophagic cargo (4). Besides its role in mobilizing endogenous macromolecules for meeting the cell’s energetic demands when extracellular nutrients are scarce, autophagy contributes to the maintenance of organelle homeostasis and the avoidance of proteotoxic stress, thereby attenuating or avoiding age-associated processes and mediating cytoprotection (5).

In this Review we discuss recent evidence indicating that nutritional, pharmacologic, and genetic manipulations to extend life span and/or health span often (or possibly always) stimulate autophagy, and that increasing autophagic flux mechanistically contributes to the extension of longevity (Table 1).

Nutrient and growth hormone signaling are master regulators of autophagy

The discovery of different genetic and pharmacologic interventions affecting autophagy has been facilitated by a detailed molecular description of the autophagic machinery, which is highly conserved among a wide spectrum of eukaryotic model organisms, ranging from the unicellular yeast Saccharomyces cerevisiae to metazoans including the nematode Caenorhabditis elegans, the fruitfly Drosophila melanogaster, and mammals (6). The initial identification of autophagy-related genes (ATGs) was accomplished in S. cerevisiae (4), in which autophagy is essential for the response to nutrient starvation.

The process of autophagy can be broken down into three steps: regulation, phagophore formation, and ultimately cargo loading and degradation (Figure 1). First, extracellular signals are transmitted to the autophagic core machinery. In all organisms tested so far, the autophagic response to dwindling nutrients is regulated by upstream signaling cascades that encompass the nutrient sensor kinases TOR, ribosomal protein S6 kinase (S6K), and RAC-α serine/threonine-protein kinase (Akt). Intuitively, downregulation of these pathways (e.g., under nutrient or growth factor depletion) results in an upregulation of autophagic activity. In turn, other kinases such as the cellular energy status–sensing AMPK and the deacetylase sirtuin 1 (SIRT1) are positive regulators of autophagy (Figure 2 and refs. 5, 7).

Caloric restriction (CR) is the most effective strategy to induce autophagy, as it activates multiple regulatory pathways. For example, CR results in the inhibition of TOR complex 1 (TORC1) and activation of AMPK, which in turn activates the autophagy-promoting Unc-51 like autophagy activating kinase 1 (ULK1) complex (Figure 2 and ref. 9), as well as the acetyltransferase MEC-17, which stimulates the cellular microtubule transport machinery that is indispensable for autophagy (8). Furthermore, CR stimulates SIRT1, which deacetylates and thereby activates essential
autophagic proteins (9). This interplay between acetylation and deacetylation seems to be a leitmotif of autophagy control that we discuss in some detail below.

In contrast to nutrient starvation, cellular growth signals (along with nutrient opulence) such as receptor binding of IGF-1 suppress autophagy via the activation of Akt, which inhibits the TORC1 repressor TSC1/2 (in addition to a variety of other targets), resulting in the activation of TORC1. Active TORC1 inhibits the suppression of autophagy by high acetyl-CoA levels in cells (17). Furthermore, histone H3 mutants mimicking constitutive deacetylation (by substituting of glutamine for lysine) demonstrated high constitutive levels of autophagy, while histone H3 mutants mimicking constitutive acetylation represent another layer of autophagy regulation. In addition to the well-known involvement of the sirtuin family of deacetylases in autophagy-dependent life span regulation (18, 19), two recent studies have shown that the nucleocytosolic concentration of acetyl-CoA, the sole acetyl group donor for protein acetylation, inversely correlates with the rate of autophagy in human cells, yeast, flies, and mice (20, 21).

The enemy inside: protein acetylation interferes with the autophagic response

There is rising evidence that posttranslational modifications including protein acetylation represent another layer of autophagy regulation. In addition to the well-known involvement of the sirtuin family of deacetylases in autophagy-dependent life span regulation (18, 19), two recent studies have shown that the nucleocytosolic concentration of acetyl-CoA, the sole acetyl group donor for protein acetylation, inversely correlates with the rate of autophagy in human cells, yeast, flies, and mice (20, 21). Common autophagy inducers such as rapamycin, CR, or deletion of the yeast Akt/S6K homolog SED9 failed to induce autophagy in cells in which nucleocytosolic acetyl-CoA was artificially elevated, and general protein acetylation was enhanced. These findings underscore the central role of acetyl-CoA as a repressor of autophagy. In yeast, histone H3 mutants mimicking constitutive acetylation of lysine residues (by substitution of glutamine for lysine) exhibited a low level of autophagy, while H3 mutants mimicking constitutive deacetylation (by substitution of arginine for lysine) demonstrated high constitutive levels of autophagy, presumably due to the epigenetic control of ATG gene expression. In human cells and mice, various strategies for depleting acetyl-CoA reduced the overall acetylation of cytoplasmic proteins commensurate with the initiation of autophagy (Figure 2). Depletion of acetyl-CoA reduced the enzymatic activity of the acetyltransferase EP300 in cell-free assays, and EP300 was required for the suppression of autophagy by high acetyl-CoA levels in cells (17).

Table 1. Examples of autophagy-dependent life span extension

<table>
<thead>
<tr>
<th>Genetic/pharmacologic intervention</th>
<th>Species</th>
<th>Anti-aging phenotype</th>
<th>Anti-aging phenotype abolished by</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loss of IGF signaling due to mutated daf-2</td>
<td>C. elegans</td>
<td>Elevated autophagy levels and dauer formation, life span extended by 70%</td>
<td>Knockdown of bec-1, atg-7, unc-51 (ATG homolog), or lgg-1 (LC3 homolog)</td>
<td>29</td>
</tr>
<tr>
<td>CR mutant eat-2</td>
<td>C. elegans</td>
<td>Enhanced autophagy, life span extended by 28%</td>
<td>Knockdown of bec-1 or atg-7</td>
<td>33</td>
</tr>
<tr>
<td>Null-mutant of cnb-1 (calcineurin)</td>
<td>C. elegans</td>
<td>Enhanced autophagy, mean life span extended by 31%</td>
<td>Knockdown of bec-1 or atg-7</td>
<td>30</td>
</tr>
<tr>
<td>Overexpression of HLH-30</td>
<td>C. elegans</td>
<td>Increased autophagic activity, life span extended by up to 20%</td>
<td>Knockdown of atg-18</td>
<td>55</td>
</tr>
<tr>
<td>Resveratrol treatment</td>
<td>C. elegans</td>
<td>Elevated autophagy levels, life span extended by 11%</td>
<td>Knockdown of bec-1</td>
<td>7</td>
</tr>
<tr>
<td>Spermidine treatment</td>
<td>C. elegans</td>
<td>Elevated autophagy levels, life span extended by 15%</td>
<td>Knockdown of bec-1</td>
<td>32</td>
</tr>
<tr>
<td>Muscle-specific transgenic expression of Drosophila</td>
<td>D. melanogaster</td>
<td>Autophagy partially enhanced proteostasis, life span extended by 21%</td>
<td>Proteostasis impaired by knockdown of Atg7</td>
<td>27</td>
</tr>
<tr>
<td>Brain-specific overexpression of Atf8</td>
<td>D. melanogaster</td>
<td>Enhanced neuronal autophagy, life span extended by &gt;50% in female flies</td>
<td>Not reported</td>
<td>44</td>
</tr>
<tr>
<td>Rapamycin treatment</td>
<td>D. melanogaster</td>
<td>Increased autophagy levels, decreased translation, median life span extended by 22%</td>
<td>Knockdown of Atg5 or null mutant of 4E-BP</td>
<td>68</td>
</tr>
<tr>
<td>Spermidine treatment</td>
<td>D. melanogaster</td>
<td>Elevated autophagy levels, mean life span extended by &lt;30%</td>
<td>Knockout of Atg7</td>
<td>32</td>
</tr>
<tr>
<td>Transgenic overexpression of ATG5</td>
<td>Mouse</td>
<td>Enhanced autophagy, improved insulin sensitivity and motor function, life span extended by 17%</td>
<td>Not reported</td>
<td>54</td>
</tr>
<tr>
<td>CR</td>
<td>Mouse</td>
<td>Life span extended by 51%</td>
<td>Homozygous knockout of Sirt1</td>
<td>19</td>
</tr>
</tbody>
</table>
The Journal of Clinical Investigation

This impaired autophagy is based on epigenetic effects mediated by histone (de)acetylation has not been studied. In addition to epigenetic surveillance, autophagy is controlled by several specific transcription factors including FOXO3A (Figure 2), which in turn is controlled by several deacetylases including SIRT1 and HDAC1. Hematopoietic stem cells lacking FOXO3A exhibit a reduced autophagic response to metabolic changes in the bone marrow microenvironment, compromising their long-term function and precipitating premature aging (26). Additionally, muscle-specific overexpression of FOXO in Drosophila enhances muscle proteostasis and longevity (27).

Autophagy is an integral mediator of life span extension

In laboratory conditions, the life span of model organisms such as yeast, C. elegans, and Drosophila can be extended by a plethora of nutritional, pharmacologic, or genetic manipulations. Such longevity-increasing manipulations usually fail if autophagy is inactivated (Table 1). For example, the markedly extended life span of C. elegans lacking functional insulin-like signaling (due to mutated daf-2) (28) is abrogated when the Beclin-1 ortholog BEC-1 is depleted (29). Increased longevity due to calcineurin deficiency in nematodes is reversed upon knockdown of bec-1 or the ATG7 ortholog atg-7 (30). Similarly, life span extension by depletion of the p53 ortholog CEP-1 (31), genetic or pharmacologic activation of the SIRT1 ortholog SIR-2.1 (7), or treatment with the acetyltransferase inhibitor spermidine (32) fails if essential autophagy genes are inactivated. CR-driven life span extension in C. elegans depends on the expression of SIR-2.1 and functional autophagy (33). In mice, CR correlates with enhanced autophagic activity and prolongs life span depending on the presence of SIRT1 (19). Results from a University of Washington (UW) study indicated that CR in primates extends life span (34); however, results from a study by the National Institute on Aging (NIA) indicated that CR in primates extends health span (35). This discrepancy in the observed effects on life span might be due to the different control diets of the studies, which might either reflect an unhealthy diet (UW study) or a mild CR diet (NIA study) (36). Nevertheless, both the UW and NIA studies corroborated that CR promotes health span. Similarly, fasting regimens in humans have been associated with improved health span, including beneficial effects on metabolic syndrome, cardiovascular diseases, and cancer incidence (37, 38). Still future
studies will need to clarify whether these effects on health span are autophagy dependent. Intriguingly, low protein consumption in humans and mice is associated with reduced risk for age-related diseases and mortality, probably through reduced signaling of IGF-1, which is an important negative regulator of autophagy (38). Reduced supply of the amino acid methionine increases longevity across species, possibly by activation of a CR-like state, and in yeast, methionine restriction extends life span in an autophagy-dependent manner (39).

Unfortunately, it is not possible to investigate the causal involvement of autophagy on life span extension in mice because the constitutive inactivation of essential autophagy genes either causes lethal developmental abnormalities or a fatal defect in the adaptation from intrauterine to postnatal metabolism (40, 41). In D. melanogaster, however, loss of Atg7 does not interfere with metamorphosis and rather affects physiologic neuronal functions in the adult animal (42), meaning that the effects of autophagy defects on longevity can be studied. There are indeed several reports demonstrating that autophagy-deficient flies fail to respond to longevity-extending regimens that are successful in autophagy-competent strains (Table 1).

A plethora of studies report that reduced levels of key autophagy regulators such as ULK1, ATG7, LC3/ATG8, or Beclin-1 accelerate aging in yeast, nematodes, flies, and rat pancreatic cells, accompanied by age-associated pathologies such as damaged mitochondria, reduced cardiac performance, lipid accumulation, and muscle degeneration (43–45). Deficient autophagosome formation resulting from a loss-of-function mutation of ATG16L1 has been linked to the pathogenesis of Crohn’s disease (46). Furthermore, ATG16L1 deficiency led to increased levels of the pro-inflammatory cytokine IL-1β in mice (47). Autophagy is also involved in immunogenic signaling by ATP replenishment and subsequent ATP release into the extracellular space (48), underscoreing the relevance of autophagy for the regulation of inflammatory processes (17). Although the genome-wide association studies conducted thus far have failed to demonstrate any reproducible link between human longevity and polymorphisms in autophagy-relevant genes, some studies suggest a link between autophagy and age-related diseases, such as frontotemporal dementia (49), breast cancer (50), and colorectal cancer (51). These findings indicate that effects of autophagy gene polymorphisms on (decreased) longevity might be preceded and possibly concealed by associated fatal pathologies, corroborating the significance of autophagy for health span extension. Given the importance of autophagy for embryonic development (52), it is tempting to speculate that many loss-of-function mutations in autophagy-relevant genes are not detectable due to prenatal lethality.

**Autophagy induction suffices to promote longevity**

Logically, the demonstration that autophagy deficiency can accelerate aging suggests that enhanced autophagic activity should prolong health span, especially if normal physiologic autophagy levels were insufficient to counteract age-associated cellular damage (53). Genetic manipulations solely designed to increase autophagy are able to extend life span in several species. For instance, transgene-enforced overexpression of the pro-autophagic protein ATG5 enhanced the life span of mice and improved several features of aging, including leanness, insulin sensitivity, and impaired motor function. Furthermore, embryonic fibroblasts originating from ATG5 transgenic mice showed higher stress resistance, which was dependent on functional autophagy (54). Consistently, overexpression of HLH-30, the homolog of the mammalian transcription stimulator, was found to extend life span in C. elegans (55). Overexpression of other key elements of the autophagic machinery such as ATG12 or LC3/ATG8 contributed to improved life span and mitochondrial maintenance in a human in vitro model of aging (56),
which suggests that the beneficial effects of sustained expression of pro-autophagic proteins can be corroborated in the human system, or at least in human cells. There is also evidence that induction of autophagy in the nervous system is particularly important, as brain-specific overexpression of LC3/ATG8 in D. melanogaster is sufficient to prolong life span (44) and mice lacking the polyglutamine stretch of huntingtin display elevated autophagy levels in the brain that were coupled to increased longevity (57). However, it is unknown whether the pathologically expanded polyglutamine stretch of mutant huntingtin associated with Huntington’s disease is responsible for the commonly observed autophagy defects (58).

CR is a simple nutritional intervention that potently stimulates autophagy, but it is generally judged to be contraindicated for broad clinical application because it causes weight loss, compromises wound healing, and generates discomfort (59). Therefore, pharmacologic induction of autophagy has been pursued extensively in the last decade for the treatment of age-associated pathologies, in particular neurodegenerative diseases. The TOR inhibitor rapamycin is a potent autophagy inducer (via inhibition of TORC1) that extends life span in a variety of organisms (Figure 3 and refs. 60–64) yet provokes severe side effects such as insulin resistance (65), glucose intolerance (66), testicular degeneration, and cataracts (63). Most of these side effects have been attributed to the chronic inhibition of TORC2 (67). Therefore, much effort is being invested in the discovery of TORC1-specific rapalogs, which should cause fewer side effects. Importantly, longevity extension by rapamycin in Drosophila is abrogated by deleting either 4E-BP1 or Atg5 (68). Therefore, the question arises whether (ATG5-dependent) autophagy and (4E-BP1-dependent) translation control different TORC1-mediated longevity pathways, or whether autophagy and translation converge on a common pathway that might affect proteostasis.

The natural phenol resveratrol, an activator of deacetylases (in particular SIRT1), induces autophagy and extends the life span of yeast, flies, and nematodes (Figure 3 and refs. 18, 69). Although resveratrol does not promote longevity in mice fed standard chow, it can improve the health and increase the life span of mice fed a high-fat, Western-style diet (70, 71). Interestingly, administration of (polyphenol-rich) coffee to mice has also been shown to induce autophagy with a concomitant decrease in protein acetylation (72). Naturally occurring polyamines, which are inhibitors of acetyltransferases, also mediate beneficial longevity-extending effects. The polyamine spermidine is a potent acetyltransferase inhibitor and likely acts by inhibiting protein acetylation in cytoplasmic and nuclear proteins (Figure 3 and ref. 73). Thus, spermidine prolongs life span of yeast, flies, and nematodes in an autophagy-dependent fashion (32). Increased dietary polyamine intake also extends the life span of short-lived mouse strains and the health span of long-lived mouse strains (74). Genetic engineering of the gut microbiome to increase polyamine synthesis in the gut also prolongs the life span of mice (75). The brain concentration of endogenous spermidine positively correlates with memory capacity in Drosophila. Moreover, external supply of spermidine can avoid the memory impairment that usually is associated with aging in flies. The positive effect of spermidine on cognitive decline is abolished by knockout of Atg7, which indicates that these effects are autophagy dependent (76). Taken together, these results suggest that agents that favor pro-
tein deacetylation either by stimulating deacetylases (such as resveratrol) or by inhibiting acetyltransferases (such as spermidine) may extend longevity of model organisms. Whether this concept is broadly applicable remains to be explored. Moreover, the concept that deacetylase activators and acetyltransferase inhibitors can synergistically induce autophagy in cultured human cells and in mice (73) remains to be confirmed in experiments that address the anti-aging effects of such combination treatments.

Mechanisms that mediate the pro-survival effects of autophagy

Proteostasis. The principal cytoprotective function of autophagy is believed to be related to its capacity to remove proteotoxic aggregates that accumulate with aging (77). Several age-related neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease, and ALS are linked to the accumulation of proteinaceous debris (78). Cellular programs that favor a eukaryotic state, such as the protein-degrading ubiquitin-proteasome system or the ER-localized unfolded protein response, only eliminate relatively small protein oligomers. In contrast, autophagy is endowed with the capacity to remove larger protein aggregates (79). Prolonged rapamycin treatment retards the clinical manifestation of AD in mouse models (80), and various autophagy inducers such as trehalose, rapamycin, and spermidine slow disease progression in mouse models of ALS (81, 82). Moreover, maintenance of a juvenile level of autophagy postpones age-related memory impairment in Drosophila (76).

Metabolism. Besides its canonical role in proteostasis, increasing evidence substantiates the involvement of autophagy in metabolism beyond a solely replenishing function. For example, it has been shown that lipid droplets, cellular organelles that regulate lipid homeostasis, can be degraded by the autophagic machinery by a process called lipophagy. Since autophagy levels have been shown to decrease with age, this impairment of bulk mobilization of lipid stores might contribute to age-related hepatic lipid accumulation and related pathologies, including hepatic steatosis (83). Of note, the lipophagic response to starvation in mice and C. elegans is transcriptionally activated by TFEB and its homolog HLH-30, respectively (84). Mice with liver-specific overexpression of TFEB were rescued from dietary-induced obesity and metabolic syndrome, but only when autophagy was functional (85). Interestingly, recent evidence from studies in D. melanogaster suggests that spermidine treatment alters organismal lipid profiles in an autophagy-dependent manner (86). It remains to be investigated whether a non-specific change in lipid flux or selective modulation of some lipid species, e.g., by shifting saturation states (87), contributes to the beneficial effects of autophagy.

Vice versa, excessive lipid levels — in particular, excessive levels of free fatty acids — have been shown to inhibit autophagy by impeding the fusion of autophagosomes with lysosomes (88). Similarly, dietary lipids were reported to alter lysosomal lipid profiles and to thereby interfere with autophagic pathways (89). Accordingly, mice fed a high-fat diet depend on adiponectin-mediated activation of autophagy in muscle cells to overcome insulin resistance (89).

Importantly, lipid-driven disturbance of autophagy might be strictly tissue specific, as some studies have demonstrated elevated levels of autophagy in adipose tissue from obese patients (90, 91). In turn, the resulting mobilization of triglycerides might block lipophagy in hepatocytes and thus contribute to obesity-associated maladies in trans (83, 92). Furthermore, inhibition of adipocyte lipophagy provokes elevated pro-inflammatory cytokine levels, which strengthens the model of a compensatory autophagic response in adipose tissue (90). Therefore, tissue-specific (e.g., liver-specific) activation of autophagy might be a possible strategy to prolong health span in obesity-related disorders.

Whether similar autophagy-dependent mechanisms also influence other metabolic fluxes, either directly by targeting specific organelles or indirectly by balancing enzyme levels, remains to be investigated.

Programmed cell death. Upon autophagy activation, Beclin-1 also mediates crosstalk to the apoptotic machinery by liberating the anti-apoptotic protein Bcl-2. This mechanism might ensure that cellular damage can be cleared by autophagy before it induces unwarranted cell death, especially in post-mitotic cells like neurons (93). As described above, the autophagic machinery can also detect and dispose damaged mitochondria that otherwise release pro-apoptotic factors and harmful reactive oxygen species, thereby offering cellular self-rescue (94). This mechanism might contribute to the commonly observed increase of autophagy in skeletal muscle myopathies. However, skeletal muscle-specific knockout of ATG5 or ATG7 in mice does not ameliorate but instead aggravates myopathy phenotypes (95, 96). Therefore, autophagy might act as a maintenance mechanism for muscle mass and counteract age-related muscle atrophy (97). Along these lines, exercise, which is generally believed to protect against a variety of age-related diseases, reportedly induces autophagy in skeletal muscle by a mechanism controlled by Bcl-2 (presumably through interaction with Beclin-1) (98).

Hormesis. Hormesis is a commonly observed phenomenon in which exposure to low doses of stressors induces resistance to subsequent higher doses of the same stressor. Although the beneficial effects of hormesis are well known and already taken advantage of, e.g., in case of ischemic preconditioning, its molecular basis is still poorly described (99). Autophagy has been suggested to mediate this protective state following some forms of hormetic preconditioning, such as low-dose treatment with agents that liberate Bcl-2 from Beclin-1 or the apoptosis inducer zebromine (100, 101). Thereby, autophagy might govern preemptive cellular detoxification that could also render the cell more resistant to age-related stresses such as protein aggregates or reactive oxygen species (99).

Inflammation. At the organismal level, the age-related reduction in autophagy correlates with a variety of archetypal senescence-related symptoms including a general increase in smoldering inflammation that is referred to as “inflammaging” (102). Autophagy might facilitate the clearance of damaged (and potentially harmful) cells by maintaining effective efferocytosis as it reduces the propensity of leukocytes to produce pro-inflammatory cytokines (103-105).

Oncogenesis. Autophagy defects have also been connected to cancer development, as this has been extensively documented in mice expressing reduced levels of autophagy-relevant genes such as those encoding Beclin-1 or its interactors UV radiation resistance–associated gene protein (UVRAG) and Bcl-2-modifying factor 1 (BMFI) (106). Whether a general age-related defect
Conclusions and outlook

Although there is little doubt that autophagy has potent anti-aging properties, it remains mostly unknown how such positive effects can be achieved in mechanistic terms. We speculate that three major functions may contribute to cytoprotection by autophagy: (a) buffering of cellular stress in conditions of fluctuating nutrient availability by enhanced provision of substrates for bioenergetic metabolism and anabolic reactions, (b) removal of dysfunctional and harmful organelles, including uncoupled mitochondria, and (c) clearance of aggregate-prone, potentially toxic proteins. On the organismal level, these functions may be expanded by the immunoregulatory properties of autophagy as well as by the cell-autonomous and the immunosurveillance-mediated suppression of oncogenesis (Figure 3).

An important objective for autophagy research in forthcoming years will be the identification of causal (instead of correlative) connections between autophagy and aging. We surmise that this goal will be facilitated by the identification of specific, highly potent pharmacologic activators or inhibitors of autophagy, as well as by the generation of sophisticated mouse models in which autophagy can be genetically switched on and off at will, in a spatially and temporally controlled fashion. Future studies should also encompass epigenetic and posttranslational effects, as they might have a crucial impact on the regulation and functional outcome of autophagy (20, 21, 23). Additionally, it will be necessary to assess which potential autophagy inducers are effective and applicable to humans. As we advance along these lines, we may be able to conceive novel strategies for exploiting the broad health-improving and life span–extending effects of autophagy.

Acknowledgments

We thank Sabrina Schroeder for helpful discussion and manuscript preparation. The authors acknowledge support from BioTechMed-Graz and NAWI Graz. This work was supported by Austrian Science Fund FWF (grants LIPOTOX, I1000, P23490-B12, and P24381-B20 to F. Madeo). This work was also supported by grants to G. Kroemer from Ligue Contre le Cancer (Équipe Labelisée), Agence National de la Recherche (ANR), Association Pour la Recherche sur le Cancer (ARC) of the Cancéropôle Ile-de-France, AXA Chair for Longevity Research of the Institut National du Cancer (INCa), Fondation Bettencourt-Schueller, Fondation de France, Fondation pour la Recherche Médicale (FRM), European Commission (ArtForce), European Research Council (ERC), LabEx Immuno-Oncology, SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE), SIRIC Cancer Research and Personalized Medicine (CARPEM), and Paris Alliance of Cancer Research Institutes (PACRI).

Address correspondence to: Frank Madeo, Institute of Molecular Biosciences, NAWI Graz, University of Graz, Humboldstrasse 50, A-8010 Graz, Austria. Phone: 43.316.380.8878; E-mail: frank.madeo@uni-graz.at. Or to: Guido Kroemer, INSERM U848, Institute Gustave Roussy PRI, 39 rue Camille-Desmoulins, Villejuif F-94805, France. Phone: 331.4211.6046; E-mail: kroemer@orange.fr.

18. Howitz KT, et al. Small molecule activators of sir-2 genes function as potent pharmacologic activators or inhibitors of autophagy, as well as by the generation of sophisticated mouse models in which autophagy can be genetically switched on and off at will, in a spatially and temporally controlled fashion. Future studies should also encompass epigenetic and posttranslational effects, as they might have a crucial impact on the regulation and functional outcome of autophagy (20, 21, 23). Additionally, it will be necessary to assess which potential autophagy inducers are effective and applicable to humans. As we advance along these lines, we may be able to conceive novel strategies for exploiting the broad health-improving and life span–extending effects of autophagy.

Acknowledgments

We thank Sabrina Schroeder for helpful discussion and manuscript preparation. The authors acknowledge support from BioTechMed-Graz and NAWI Graz. This work was supported by Austrian Science Fund FWF (grants LIPOTOX, I1000, P23490-B12, and P24381-B20 to F. Madeo). This work was also supported by grants to G. Kroemer from Ligue Contre le Cancer (Équipe Labelisée), Agence National de la Recherche (ANR), Association Pour la Recherche sur le Cancer (ARC) of the Cancéropôle Ile-de-France, AXA Chair for Longevity Research of the Institut National du Cancer (INCa), Fondation Bettencourt-Schueller, Fondation de France, Fondation pour la Recherche Médicale (FRM), European Commission (ArtForce), European Research Council (ERC), LabEx Immuno-Oncology, SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE), SIRIC Cancer Research and Personalized Medicine (CARPEM), and Paris Alliance of Cancer Research Institutes (PACRI).

Address correspondence to: Frank Madeo, Institute of Molecular Biosciences, NAWI Graz, University of Graz, Humboldstrasse 50, A-8010 Graz, Austria. Phone: 43.316.380.8878; E-mail: frank.madeo@uni-graz.at. Or to: Guido Kroemer, INSERM U848, Institute Gustave Roussy PRI, 39 rue Camille-Desmoulins, Villejuif F-94805, France. Phone: 331.4211.6046; E-mail: kroemer@orange.fr.
54. Minozzi S, Rockenfeller R, Smith TK, Carmona-Gutierrez D. Spermidine feeding decreases age-related locomotor activity loss and